Introduction
Nearly 1 million new cases of gastric cancer (GC) are estimated to occur each year, making it the fifth most common malignancy in the world (GLOBOCAN 2012) [1] . There is substantial geographic variation in the incidence of GC, with the highest rates in East Asian populations and the lowest in North American populations [2] ; certain environmental factors such as Helicobacter pylori infection, dietary factors, and smoking patterns may contribute to these disparities [3] [4] [5] . The study of the genetic basis of GC, including host genetic susceptibility, has improved understanding of the pathogenesis of this disease and has highlighted the role of infection and chronic inflammation in GC.
Precision therapy research has opened up opportunities for cancer treatments, commercialization, and personal understanding of highly heterogeneous human tumors. Advances in high-throughput cancer genome sequencing and profiling technologies are rapidly transforming the development and approval of targeted agents, paving the way for a more precise therapeutic selection for individual patients. Multiple signaling pathways have been identified as key drivers of cancer patient outcome and therapeutic response through genetic and epigenetic aberrations, allowing for the expansion of GC classification from epidemiology to molecular disease biology.
Given the power and throughput of next-generation sequencing (NGS), the application of this technology is driving the development of new therapies by targeting the most frequently occurring molecular abnormalities. However, much of our knowledge of somatic mutations has been obtained from tumors of Western Caucasian patient populations, while the greatest burden of GC is among Eastern Asian patient populations. This raises the question of whether GCs from patients of Asian and Caucasian descent exhibit different somatic genomic alterations, leading to an inadvertent disparity in the development and application of new therapies.
Materials and Methods

Integrating Multi-Country Sequencing Somatic
Mutation Data from the Cancer Genome Atlas
Mutation data of Hong Kong (N = 100) [6] and Japanese patients (N = 30) [7] were identified in genes relevant to GC (Table 1) using cBioPortal, while the data of Singaporean (N = 15) patients were obtained from a published study by Zang et al. [8] . TCGA stomach adenocarcinoma cases (N = 295) were obtained, with relevant clinical and somatic mutation (level 2) data, from the TCGA web portal (tcga-data.nci.nih.gov; June 2014). These TCGA cases were further filtered with 1000 genomes and re-annotated as described in Sect. 2.3 Mutation rates were calculated among patient groups defined by country of origin, and the TCGA identifier was used as a linker to clinical and genomic data. Finally, Germany (N = 38), Poland (N = 32), Russia (N = 80), South Korea (N = 31), Ukraine (N = 38), US (N = 22), and Vietnam (N = 22) GC samples were obtained with mutation frequencies across relevant genes ( Fig. 1 ; electronic supplementary Table 1 ). [9, 10] . Gastric adenocarcinoma and signet-ring cell carcinoma were included (electronic supplementary  Table 3 ). Primary and metastatic samples from 33 GC patients (self-identified race = 'White') were available for analysis. In all cases, tissue and clinical data were collected on patients, under Institutional Review Board (IRB) approval, as part of the Total Cancer Care TM (TCC) project [9] . Approval from the Moffitt Cancer Center IRB was obtained to analyze clinical data for this study (electronic supplementary Table 2 ) from patients who consented to the TCC protocol and whose tumors were profiled with targeted sequencing.
All tumors were collected from curative survival resections and snap frozen in liquid nitrogen within 15-20 min of extirpation. Tumors then underwent a macrodissection quality control process to ensure [80% tumor was present in the specimen that underwent sequence analysis. DNA was then extracted from 33 GC specimens, followed by targeted sequencing using a custom designed Agilent SureSelect Capture (Agilent Technologies, Inc., Santa Clara, CA, USA). Overall, 1321 cancer-associated genes were selected by a joint committee (Merck Co., Inc. and Moffitt Cancer Center) for hybrid capture and sequencing. Capture probes for the 1321 genes were based on the Agilent SureSelect 50 MB capture.
Targeted Exome Sequencing Workflow and Analysis at the Moffitt Cancer Center
Tumor samples from the TCC project were subjected to genomic capture [performed by the Beijing Genomics Institute (BGI), Shenzhen, using SureSelect custom designs targeting 1321 genes (Agilent Technologies, Inc)] and massively parallel sequencing [performed by BGI, Shenzhen, using GAIIx (Illumina, Inc., San Diego, CA, USA)]. Sequences were aligned to the hs37d5 human reference using the Burrows-Wheeler Aligner (BWA) [11] , and insertion/deletion realignment, quality score recalibration, and variant identification were performed using the Genome Analysis ToolKit (GATK) [12] . Sequence variants were annotated using ANNOVAR [13] . Additional contextual information was incorporated, including allele frequency from the 1000 Genomes Project and the National Heart Lung and Blood Institute (NHLBI) Exome Sequencing Project, in silico functional impact predictions, and observations from the Collection of Somatic Mutations in Cancer (COSMIC). Somatic mutations were enriched by filtering out variants observed in the 1000 Genomes Project and observed at [5% in an internal normal sample dataset (electronic supplementary Table 2 ).
Statistical Analysis Comparing Asian and Caucasian Gastric Cancer Patient Populations
We selected GC patients from Hong Kong, Vietnam, South Korea, Singapore, and Japan as the Asian group (n = 198), while GC patients from the US, Germany, Poland, Russia, and Ukraine were included in the Caucasian group (n = 243). Somatic mutation frequency was calculated as GC patients bearing mutation for each gene divided by the total number in each ethnic group (198 for the Asian group and 243 for the Caucasian group). We used the exact binominal test to examine statistically significant differences in somatic mutation frequencies for 11 genes (electronic supplementary Table 4 ). Statistical analysis was performed using open source statistical software R (v3.1.0), and world maps were also drawn using the R packages 'rworldmap' and 'rgdal'.
Results
Assessment of whole exome sequencing/whole genome sequencing (WES/WGS) studies in Asian patients identified 11 genes that were consistently mutated in GC. Somatic mutation frequencies of five of those genes-APC, ARID1A, KMT2A, PIK3CA, and PTEN-were significantly different between the Asian and Caucasian geographic populations (Table 1 ; electronic supplementary figures). For five genes, the mean frequency was higher in Caucasians compared with Asian patient populations. More detailed information for these genes and their somatic mutations is described below. The mean frequency of APC alteration was more than twice as high in Caucasian patients than Asian patients (Fig. 2) , with the highest frequency in German patients and the lowest in patients from Singapore. Within patients from Asian regions, the frequency was highest in South Korea (16.1%) and lowest in Singapore (0%), whereas in Europe the frequency was highest in Germany (26.3%) and lowest in Ukraine (5.3%).
Overall, 19 of 198 (9.6%) Asian GC patients had PIK3CA mutations, compared with 45 of 243 (18.5%) in the Caucasian population (p = 0.01). Among Asian countries, South Korea GC patients harbored the highest alteration frequency of APC, ARID1A, GLI3, PIK3CA, and KMT2A (Fig. 3) . Furthermore, PIK3CA, GLI3, and ARID1A mutation frequency was higher than any assessed cohorts. China (Hong Kong) has the highest mutation rates of ACVR2A (8%) and PTEN (4%) among Asian countries, compared with the Asian mean of 4% for ACVR2A and 2.5% for PTEN. Interestingly, other than China (Hong Kong), no other Asian GC patients harbored ACVR2A alterations. Although PTEN alterations were relatively frequent in Chinese patients compared with other Asian countries, it was altered less often than Caucasian patients (9.1%). Contrasting with the relatively high frequency of ACVR2A and PTEN, Chinese GC patients harbored the lowest frequency of KMT2A (2%) and PIK3CA (2%) alterations.
Japanese GC patients harbored the lowest CTNNB1, GLI3, PTEN, SMAD4, and TP53 alterations (3, 3, 0, 3, and 37%, respectively) among Asian countries, compared with mean values of 5.6, 11.1, 2.5, 6.6, and 51.5%, respectively, across the Asian region. Alterations in ACVR2A, APC, CDH1, and PTEN in Singaporean GC patients were absent, while alterations in ARID1A were lowest among Asian countries (13.3% vs. Asian mean of 21.7%). On the other hand, CTNNB1 alteration rates in Singaporean GC patients were highest among Asian GC patients (13.3% vs. Asian mean of 5.6%).
Significant heterogeneity was seen across the Caucasian cohorts; however, consistent patterns could not be detected. German patients had the highest frequency of APC and KMT2A alterations, but the lowest frequency for CDH1. Polish GC patients harbored the highest CDH1 alteration rates but the lowest KMT2A and SMAD4 alteration rates, while Ukrainian GC patients had the highest SMAD4, PIK3CA, and GLI3 alteration rates and lowest TP53 and APC alteration rates. The Caucasian patient population had a larger variation of KMT2A alteration compared with the Asian group, ranging from 3.1 to 18.4% and 2-9.7%, respectively. The mean KMT2A mutational frequency was three times higher in Caucasian GC patients compared with Asian GC patients (p = 0.003) (Fig. 3) .
Dramatic differences were seen in the PTEN gene, mutation rates were 13.8 and 13.6% for Russian and American GC patients, and PTEN alterations were absent in Vietnamese, Singaporean, and Japanese GC patients. PTEN mutation rates were higher among Caucasian GC patients compared with Asian GC patients (p = 0.008) (Fig. 4) .
Discussion
Understanding geographic differences in somatic mutation frequency is more than an academic interest and is important for rational global introduction of targeted cancer drugs due to the highly heterogeneous therapeutic responses in their worldwide applications. For example, recent phase II and III trials suggested that epidermal growth factor receptor (EGFR) inhibitors were more effective for Asian cancer patients than patients in other ethnicities, a characteristic that parallels a much higher incidence of EGFR-activating mutations among Asian patient populations [14] [15] [16] [17] . Consequently, clinical studies focusing on EGFR-targeted therapies have rapidly advanced, based on the fact that Asian patients harboring the EGFR somatic mutation account for 30-40% of total patients, significantly higher than that of patients from European descent [18] [19] [20] [21] .
It has been observed thus far that ethnic factors are likely to contribute to the disappointing results in advanced GC, therefore these factors should be carefully taken into account when conducting global clinical trials across different ethnic populations [22] [23] [24] [25] . Stratified analysis by race/ethnicity may need to be performed in such global studies in order to maximize the benefits of alternative precision therapeutic modalities. For instance, the phase III GRANITE-1 trial, the first global gastric antitumor trial with everolimus (NCT00879333), did not show a significant survival benefit from everolimus beyond best supportive care for the worldwide cohort of advanced GC patients whose disease relapsed after one or two lines of systemic chemotherapy [22] . However, when ethnic subgroups were examined, a 15% reduced risk of death was seen for Caucasian patients (US, Canada, Israel, Russia, Mexico, Colombia, Brazil, Venezuela, Australia, and New Zealand) compared with patients in Asia (China, Hong Kong, Japan, Korea, Taiwan and Thailand) [22] . Di Nicolantonio and colleagues demonstrated that PIK3CA mutations can sensitize cancer cells to everolimus [26] . Interestingly, our study demonstrated that PIK3CA mutation rates were almost twice as high in Caucasian GC patients as they are in Asian cases (18.5 vs. 9.6%, p = 0.012), which suggests a mechanistic basis behind the differential response to everolimus in Caucasian GC patients. Even if Asian patients with PIK3CA mutations may have also been more likely to respond to the drug, the effect could have been masked in the overall analysis by a low mutation frequency among Asian patients. Initial investigations on biomarkers in the PI3K/Akt/mTOR pathway are ongoing and the results are eagerly awaited [22] .
Unfortunately, in-depth understanding of the molecular underpinnings of GC is currently lagging compared with many other cancers of similar incidence and morbidity. Thanks to recent advances in NGS technology, common somatic alterations (PTEN, PIK3CA, and TP53) are rapidly being discovered, some of which are being pursued clinically. For instance, a multi-national (US, Germany, Japan, South Korea, Switzerland, and Taiwan) phase I study of the PIK3CA inhibitor BYL719, in combination with the HSP90 inhibitor AUY922, enrolled advanced GC patients carrying either a molecular alteration of PIK3CA or an amplification of HER2 (NCT01613950). Also, a phase II trial of AZD5363 (Akt inhibitor) plus paclitaxel/AZD2014 (mTOR inhibitor) plus paclitaxel in biomarker negative (PIK3CA/MEK/RAS/TP53/MET) advanced gastric adenocarcinoma patients as second-line chemotherapy is currently enrolling patients (NCT02449655). Furthermore, a single-arm, phase II study of AZD1775 (Wee1 G2 checkpoint serine/threonine protein kinase inhibitor) in combination with paclitaxel in patients with advanced gastric adenocarcinoma harboring TP53 mutation as a second-line chemotherapy (NCT02448329) is also currently recruiting participants. These studies should yield greater understanding of the translational impact of mutated biological pathways, in addition to the anticipated therapeutic benefits. Many novel somatic gene targets (CDH1, ARID1A, KMT2A, ACVR2A, CTNNB1, GLI3, SMAD4, and APC) have also been identified to be of great interest [6] [7] [8] . Our study demonstrated that Caucasian GC patients have higher mutation rates of APC, ARID1A, KMT2A, PIK3CA, and PTEN genes than Asian patients. The mechanism responsible for the high frequency of these mutations in Caucasian patients will be a subject of great interest. In the near future, considerably larger Asian clinical trials will be needed to understand the ethnic differences in these biomarkers and their somatic mutation frequencies. If frequencies of such biomarkers are lower in Asian populations (as we have shown for mutation rates in five genes), more patients may need to be screened for eligibility to complete sufficiently powered biomarker-driven trials.
Global GC drug development is largely performed in Western countries, while considerable somatic-based prognostic indicator models of GC were identified and developed in Asian countries. Tan et al. identified two major intrinsic genomic subtypes as a statistically significant covariate that is associated with survival time following adjuvant, 5-fluorouracil-based therapy [27] . Cho et al. [28] identified and validated robust prognostic markers (CTNNB1, EXOSC3, TOP2A, LBA1, LZTR1, and CCL5) in Korean GC patients and developed a prognostic risk score that can be easily translated into clinical practice. Lei et al. identified three subtypes of gastric adenocarcinoma: proliferative, metabolic, and mesenchymal, based on gene expression patterns [29] . Results from detailed molecular and/or pathological GC studies from Asian populations are promising but it remains questionable whether they can be fully extrapolated to Caucasian populations. Our study has shown that there can be significant biomarker frequency differences across populations, suggesting that the potential clinical impact of a biomarker may also vary across populations. Although personalized research into these differences has just begun, molecular models should be carefully considered to help transform clinical practice.
The traditional approach of one size fits all clinical trials, and attempting to find a single optimal therapy to apply across GC, has likely contributed to slow progress on treating this disease with novel targeted drugs. The study from TCGA has enlightened understanding of this highly heterogeneous disease by cataloging genomic characteristics across a spectrum of GC patients from large international groups [30] . Our analyses utilizing TCGA and other databases have found discordance of somatic mutations in specific clinically relevant genes between the two ethnic groups. Differences were also observed among countries with similar ethnic populations, suggesting that it also important to consider local-regional differences as well as national/ethnic diversities.
There are several limitations in our current study. First, differences in mutation rates between different ethnic groups may also be due to different depths or other technologic aspects of sequencing methods. Also, although TCGA used similar sequencing and analysis methods for each sample, sample sizes and representative countries of Asian patient populations were limited. Despite these limitations, comparisons within TCGA showed the same trends as our overall analysis, which at least partially confirmed the observations and analysis results obtained in our global comparison.
Conclusions
It remains important for future large molecular cancer studies to include diverse patient populations in proportions that allow conclusions to be drawn. We believe that our findings help to understand the multifaceted nature of GC, underscore the importance of molecularguided personalized medicine, and provide practical implications for further study and future personalized GC treatments.
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